NIRCO med‎ > ‎drugs‎ > ‎Antithrombotika‎ > ‎Heparin-Gruppe‎ > ‎

unfractionated heparin (UFH)

Indikationen/Anwendungsmöglichkeiten: in a surgical population 3x5000E unfractionated heparin subcutaneously yields subtherapeutic levels of aFXa activity. Patients with subcutaneously unfractionated heparin displayed a hypercoagulable whole blood coagulation profile (25 patients). In contract, this hypercoagulable profile was corrected in patients with intravenous heparin (25 patients). As there was no placebo control group in this trial, no conclusions can be made about whether subcutaneous unfractionated heparin had any anticoagulant effect (2).

Revertieren: one advantage of UFH is that it can be completely neutralized with protamine sulfate - unlike LMWHs (1).

Eigenschaften/Wirkungen: UFH inactivates both thrombin and factor Xa, catalyzed by binding to antithrombin (also called antithrombin III) (1).

Referenzen:
  1. Novel Oral Anticoagulants: Implications in the Perioperative Setting. Anesthesiology. 2010;113:726–45: full text | pdf | periop.
  2. Sara S. Cheng et al. Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. Intensive Care Med. 2012;38:642-648: full text | pdf.